{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:52:28Z","timestamp":1781643148260,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030774","name":"Sociedade Brasileira de Reumatologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease in which achieving remission is the most effective strategy to prevent progression and optimize long-term outcomes. The performance of commonly used disease activity indices has not been well validated in the Brazilian RA population. This study aimed to evaluate the agreement between CDAI\/SDAI and the revised Boolean 2.0 remission criteria, which served as the reference standard, and to identify the most accurate CDAI and SDAI remission cut-offs in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional analysis of baseline data from a Brazilian Cohort study, which included 840 patients from 11 public hospitals in Brazil. Disease activity was assessed using DAS28-CRP, DAS28-ESR, SDAI, CDAI, and Boolean 1.0\/2.0. Agreement was assessed using Cohen\u2019s kappa, and optimal remission cut-offs were determined through ROC curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study population was predominantly female (89.8%), with a mean age of 57 years and a median disease duration of 12 years. DAS28-CRP showed the highest remission rate (39.2%), whereas Boolean 1.0 showed the lowest (15.1%). Strong agreement was found between Boolean 2.0, and both the SDAI (\u03ba\u2009=\u20090.775) and CDAI (\u03ba\u2009=\u20090.692). ROC analysis revealed that the most accurate remission cut-offs were SDAI\u2009\u2264\u20094.3 and CDAI\u2009\u2264\u20093.9, which increased remission detection by 5.9% and 6.2%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In our cohort, SDAI\u2009\u2264\u20094.3 and CDAI\u2009\u2264\u20093.9 were the values most closely aligned with Boolean 2.0 remission. These adjusted cut-offs may help minimize overtreatment in resource-limited settings. Prospective studies assessing function, radiographic progression, and quality of life are warranted to confirm their validity in the Brazilian population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-026-00532-4","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:08:19Z","timestamp":1773389299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are global definitions enough? Revisiting CDAI and SDAI remission cut-offs in Brazilian Rheumatoid Arthritis patients"],"prefix":"10.1186","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-5925","authenticated-orcid":false,"given":"Lucas Castro","family":"Pires","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0444-738X","authenticated-orcid":false,"given":"Alisson","family":"Pugliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9245-7504","authenticated-orcid":false,"given":"Cleandro Pires","family":"de Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3073-2929","authenticated-orcid":false,"given":"Vitor Alves","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0254-4330","authenticated-orcid":false,"given":"Manoel Barros","family":"Bertolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2884-2210","authenticated-orcid":false,"given":"Ana Paula Monteiro Gomides","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-1723","authenticated-orcid":false,"given":"Rina Dalva Neubarth","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-1695","authenticated-orcid":false,"given":"Leticia Rocha","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6366-8401","authenticated-orcid":false,"given":"Sebasti\u00e3o Cezar","family":"Radominski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3910-4988","authenticated-orcid":false,"given":"Ivanio Alves","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3865-3739","authenticated-orcid":false,"given":"Maria Fernanda Resende","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2585-3870","authenticated-orcid":false,"given":"Paulo","family":"Louzada Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0644-3139","authenticated-orcid":false,"given":"Maria de F\u00e1tima Lobato","family":"da Cunha Sauma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3547-5674","authenticated-orcid":false,"given":"Karina Rossi","family":"Bonfiglioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-7912","authenticated-orcid":false,"given":"Claiton Viegas","family":"Brenol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8182-5121","authenticated-orcid":false,"given":"Licia Maria Henrique","family":"da Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-569X","authenticated-orcid":false,"given":"Geraldo da Rocha Castelar","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"532_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. The Lancet. Elsevier. 2016;388:2023\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8.","journal-title":"Elsevier"},{"key":"532_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41584-022-00827-y","volume":"18","author":"A Finckh","year":"2022","unstructured":"Finckh A, Gilbert B, Hodkinson B, Bae S-C, Thomas R, Deane KD, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18:591\u2013602. https:\/\/doi.org\/10.1038\/s41584-022-00827-y.","journal-title":"Nat Rev Rheumatol"},{"key":"532_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42358-018-0005-0","volume":"58","author":"LMH da Mota","year":"2018","unstructured":"da Mota LMH, Kakehasi AM, Gomides APM, Duarte ALBP, Cruz BA, Brenol CV, et al. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis. Adv Rheumatol. 2018;58:2. https:\/\/doi.org\/10.1186\/s42358-018-0005-0.","journal-title":"Adv Rheumatol"},{"key":"532_CR4","doi-asserted-by":"publisher","unstructured":"Fraenkel L, Bathon JM, England BR, St.Clair EW, Arayssi T, Carandang K, Hoboken et al.). Wiley, Ltd; 2021;73:924\u201339. https:\/\/doi.org\/10.1002\/acr.24596.","DOI":"10.1002\/acr.24596"},{"key":"532_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"key":"532_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.reumae.2024.02.009","volume":"20","author":"C Abud-Mendoza","year":"2024","unstructured":"Abud-Mendoza C, Aceves-\u00c1vila FJ, Arce-Salinas CA, \u00c1lvarez Nemegyei J, Barile-Fabris L, Dur\u00e1n-Barrag\u00e1n S, et al. Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023. Reumatolog\u00eda Cl\u00ednica (English Edition). 2024;20:263\u201380. https:\/\/doi.org\/10.1016\/j.reumae.2024.02.009.","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"key":"532_CR7","doi-asserted-by":"publisher","unstructured":"van Tuyl LHD, Felson DT, Wells G, Smolen J, Zhang B, Boers M. Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: A systematic review. Arthritis Care Res (, Hoboken.). John Wiley & Sons, Ltd; 2010;62:108\u201317. https:\/\/doi.org\/10.1002\/acr.20021","DOI":"10.1002\/acr.20021"},{"key":"532_CR8","doi-asserted-by":"publisher","first-page":"R56","DOI":"10.1186\/ar4491","volume":"16","author":"H Radner","year":"2014","unstructured":"Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther. 2014;16:R56. https:\/\/doi.org\/10.1186\/ar4491.","journal-title":"Arthritis Res Ther"},{"key":"532_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/annrheumdis-2017-211375","volume":"77","author":"G Akdemir","year":"2018","unstructured":"Akdemir G, Heimans L, Bergstra SA, Goekoop RJ, van Oosterhout M, van Groenendael JHLM, et al. Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. Ann Rheum Dis. 2018;77:111\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211375.","journal-title":"Ann Rheum Dis"},{"key":"532_CR10","doi-asserted-by":"publisher","first-page":"e004387","DOI":"10.1136\/rmdopen-2024-004387","volume":"10","author":"C Duarte","year":"2024","unstructured":"Duarte C, Jacobs JWG, Ferreira RJO, Welsing PMJ, Gossec L, Machado PM, et al. Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data. RMD Open. 2024;10:e004387. https:\/\/doi.org\/10.1136\/rmdopen-2024-004387.","journal-title":"RMD Open"},{"key":"532_CR11","doi-asserted-by":"publisher","unstructured":"Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index. Arthritis Care Res (Hoboken). 2011;63. https:\/\/doi.org\/10.1002\/acr.20621.","DOI":"10.1002\/acr.20621"},{"key":"532_CR12","doi-asserted-by":"publisher","unstructured":"Prevoo MLL, Van \u2019T, Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LBA, Van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. John Wiley & Sons, Ltd; 1995;38:44\u20138. https:\/\/doi.org\/10.1002\/art.1780380107","DOI":"10.1002\/art.1780380107"},{"key":"532_CR13","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker J-C, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68:954\u201360. https:\/\/doi.org\/10.1136\/ard.2007.084459.","journal-title":"Ann Rheum Dis"},{"key":"532_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42:244\u201357. https:\/\/doi.org\/10.1093\/rheumatology\/keg072.","journal-title":"Rheumatology"},{"key":"532_CR15","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:R796. https:\/\/doi.org\/10.1186\/ar1740.","journal-title":"Arthritis Res Ther"},{"key":"532_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.149765","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, Van Tuyl LHD, Funovits J, et al. American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011. https:\/\/doi.org\/10.1136\/ard.2011.149765.","journal-title":"Ann Rheum Dis"},{"key":"532_CR17","doi-asserted-by":"publisher","unstructured":"Studenic P, Aletaha D, de Wit M, Stamm TA, Alasti F, Lacaille D, et al. American College of Rheumatology\/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. Arthritis Rheumatol. 2023;75. https:\/\/doi.org\/10.1002\/art.42347.","DOI":"10.1002\/art.42347"},{"key":"532_CR18","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1002\/art.34543","volume":"64","author":"P Studenic","year":"2012","unstructured":"Studenic P, Radner H, Smolen JS, Aletaha D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum John Wiley Sons Ltd. 2012;64:2814\u201323. https:\/\/doi.org\/10.1002\/art.34543.","journal-title":"Arthritis Rheum John Wiley Sons Ltd"},{"key":"532_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/pm\/pnaa427","volume":"22","author":"ME Morales","year":"2021","unstructured":"Morales ME, Yong RJ. Racial and Ethnic Disparities in the Treatment of Chronic Pain. Pain Med. 2021;22:75\u201390. https:\/\/doi.org\/10.1093\/pm\/pnaa427.","journal-title":"Pain Med"},{"key":"532_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/ard.2006.054205","volume":"66","author":"E Inoue","year":"2007","unstructured":"Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407\u20139. https:\/\/doi.org\/10.1136\/ard.2006.054205.","journal-title":"Ann Rheum Dis"},{"key":"532_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00296-011-1798-x","volume":"32","author":"S-Y Park","year":"2012","unstructured":"Park S-Y, Lee H, Cho S-K, Choi C-B, Sung Y-K, Bae S-C. Evaluation of disease activity indices in Korean patients with rheumatoid arthritis. Rheumatol Int. 2012;32:545\u20139. https:\/\/doi.org\/10.1007\/s00296-011-1798-x.","journal-title":"Rheumatol Int"},{"key":"532_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12891-015-0718-8","volume":"16","author":"I Slama","year":"2015","unstructured":"Slama I, Ben, Allali F, Lakhdar T, El kabbaj S, Medrare L, Ngeuleu A, et al. Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2015;16:268. https:\/\/doi.org\/10.1186\/s12891-015-0718-8.","journal-title":"BMC Musculoskelet Disord"},{"key":"532_CR23","doi-asserted-by":"crossref","unstructured":"Song X, Wang Y-H, Li M-T, Duan X-W, Li H-B, Zeng X-F. Chinese registry of rheumatoid arthritis: IV. Correlation and consistency of rheumatoid arthritis disease activity indices in China. Chin Med J (Engl). 2021;134. https:\/\/journals.lww.com\/cmj\/fulltext\/2021\/06200\/chinese_registry_of_rheumatoid_arthritis__iv_.13.aspx","DOI":"10.1097\/CM9.0000000000001517"},{"key":"532_CR24","doi-asserted-by":"publisher","first-page":"e0278285","DOI":"10.1371\/journal.pone.0278285","volume":"17","author":"K Dissanayake","year":"2022","unstructured":"Dissanayake K, Jayasinghe C, Wanigasekara P, Dissanayake J, Sominanda A. Validity of clinical disease activity index (CDAI) to evaluate the disease activity of rheumatoid arthritis patients in Sri Lanka: A prospective follow up study based on newly diagnosed patients. PLoS One Public Libr Sci. 2022;17:e0278285\u2013. https:\/\/doi.org\/10.1371\/journal.pone.0278285.","journal-title":"PLoS One Public Libr Sci"},{"key":"532_CR25","doi-asserted-by":"publisher","unstructured":"da Castelar-Pinheiro R, Vargas-Santos G, de Albuquerque AB, B\u00e9rtolo CP, J\u00fanior MB, Giorgi PL. The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil. Adv Rheumatol. 2018;58. https:\/\/doi.org\/10.1186\/s42358-018-0017-9.","DOI":"10.1186\/s42358-018-0017-9"},{"key":"532_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s42358-020-0119-z","volume":"60","author":"APM Gomides","year":"2020","unstructured":"Gomides APM, de Albuquerque CP, Santos ABV, B\u00e9rtolo MB, J\u00fanior PL, Giorgi RDN, et al. Rheumatoid artrhitis treatment in Brazil: data from a large real-life multicenter study. Adv Rheumatol. 2020;60:16. https:\/\/doi.org\/10.1186\/s42358-020-0119-z.","journal-title":"Adv Rheumatol"},{"key":"532_CR27","doi-asserted-by":"publisher","unstructured":"Santos IA, de Oliveira RDR, Almeida SCL, Vargas-Santos AB, Amorim RBC, Gomides APM, et al. Comparison of rheumatoid arthritis composite disease activity indices and residual activity in a Brazilian multicenter study- REAL study. PLoS ONE. 2022;17. https:\/\/doi.org\/10.1371\/journal.pone.0273789.","DOI":"10.1371\/journal.pone.0273789"},{"key":"532_CR28","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10067-017-3925-x","volume":"37","author":"MO Olmez","year":"2018","unstructured":"Olmez MO, Gunal EK, Ureyen SB, Keskin H, Ozturk AB, Yeter G, et al. Comparison of composite indices with global synovitis score on ultrasound for detecting remission. Clin Rheumatol. 2018;37:1111\u20134. https:\/\/doi.org\/10.1007\/s10067-017-3925-x.","journal-title":"Clin Rheumatol"},{"key":"532_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s41927-022-00314-7","volume":"6","author":"K Janke","year":"2022","unstructured":"Janke K, Kiefer C, McGauran N, Richter B, Krause D, Wieseler B. A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis. BMC Rheumatol. 2022;6:82. https:\/\/doi.org\/10.1186\/s41927-022-00314-7.","journal-title":"BMC Rheumatol"},{"key":"532_CR30","first-page":"169","volume":"33","author":"JF Marques Neto","year":"1993","unstructured":"Marques Neto JF, Gon\u00e7alves ET, Langen LF, de OB, Cunha M, de FL, Radominski S, de Oliveira SM, et al. Multicentric study of the prevalence of adult rheumatoid arthritis in Brazilian population samples. Rev Bras Reumatol. 1993;33:169\u201373.","journal-title":"Rev Bras Reumatol"},{"key":"532_CR31","first-page":"594","volume":"31","author":"ER Senna","year":"2004","unstructured":"Senna ER, De Barros ALP, Silva EO, Costa IF, Pereira LVB, Ciconelli RM, et al. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol. 2004;31:594. http:\/\/www.jrheum.org\/content\/31\/3\/594.abstract.","journal-title":"J Rheumatol"},{"key":"532_CR32","doi-asserted-by":"publisher","first-page":"1759720X2210963","DOI":"10.1177\/1759720X221096363","volume":"14","author":"KJHL Yusun","year":"2022","unstructured":"Yusun KJHL, Jinhyun KH-AK, Kichul S. Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry. Ther Adv Musculoskelet Dis SAGE Publications. 2022;14:1759720X221096363. https:\/\/doi.org\/10.1177\/1759720X221096363.","journal-title":"Ther Adv Musculoskelet Dis SAGE Publications"},{"key":"532_CR33","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.semarthrit.2019.09.005","volume":"50","author":"D Aletaha","year":"2020","unstructured":"Aletaha D, Wang X, Zhong S, Florentinus S, Monastiriakos K, Smolen JS. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. Semin Arthritis Rheum. 2020;50:276\u201384. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.09.005.","journal-title":"Semin Arthritis Rheum"},{"key":"532_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13075-017-1346-5","volume":"19","author":"M Schoels","year":"2017","unstructured":"Schoels M, Alasti F, Smolen JS, Aletaha D. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition. Arthritis Res Ther. 2017;19:155. https:\/\/doi.org\/10.1186\/s13075-017-1346-5.","journal-title":"Arthritis Res Ther"},{"key":"532_CR35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41584-019-0279-6","volume":"15","author":"D Aletaha","year":"2019","unstructured":"Aletaha D, Smolen JS. Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nat Rev Rheumatol. 2019;15:633\u20134. https:\/\/doi.org\/10.1038\/s41584-019-0279-6.","journal-title":"Nat Rev Rheumatol"},{"key":"532_CR36","doi-asserted-by":"publisher","first-page":"100240","DOI":"10.1016\/j.lanwpc.2021.100240","volume":"15","author":"X Sun","year":"2021","unstructured":"Sun X, Li R, Cai Y, Al-Herz A, Lahiri M, Choudhury MR, et al. Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. Lancet Reg Health West Pac. 2021;15:100240. https:\/\/doi.org\/10.1016\/j.lanwpc.2021.100240.","journal-title":"Lancet Reg Health West Pac"},{"key":"532_CR37","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/ard-2023-224116","volume":"82","author":"M \u00d8stergaard","year":"2023","unstructured":"\u00d8stergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordstr\u00f6m DC, et al. Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis BMJ Publishing Group. 2023;82:1286\u201395. https:\/\/doi.org\/10.1136\/ard-2023-224116.","journal-title":"Ann Rheum Dis BMJ Publishing Group"},{"key":"532_CR38","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/annrheumdis-2016-210561","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R, et al. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017;76:1279. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210561.","journal-title":"Ann Rheum Dis"},{"key":"532_CR39","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","volume":"75","author":"GR Burmester","year":"2016","unstructured":"Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75:1081. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207628.","journal-title":"Ann Rheum Dis"},{"key":"532_CR40","doi-asserted-by":"publisher","first-page":"e004037","DOI":"10.1136\/rmdopen-2023-004037","volume":"10","author":"RF van Vollenhoven","year":"2024","unstructured":"van Vollenhoven RF, Hall S, Wells AF, Meerwein S, Song Y, Tanjinatus O, et al. Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND. RMD Open. 2024;10:e004037. https:\/\/doi.org\/10.1136\/rmdopen-2023-004037.","journal-title":"RMD Open"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-026-00532-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-026-00532-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-026-00532-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:59:44Z","timestamp":1781639984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42358-026-00532-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["532"],"URL":"https:\/\/doi.org\/10.1186\/s42358-026-00532-4","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the National Research Ethics Committee of the Ministry of Health (number: 45781015810015259). Each center also obtained approval from their respective Research Ethics Committees. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no financial or non\u2011financial competing interests related to this work. Cleandro Pires de Albuquerque, L\u00edcia Maria Henrique da Mota, Iv\u00e2nio Alves Pereira, Geraldo da Rocha Castelar Pinheiro, and Paulo Louzada Junior are members of the editorial board of Advances in Rheumatology. These roles did not influence the peer\u2011review process, editorial decision, or interpretation of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}